Ado-Trastuzumab Emtansine

Common brands: Kadcyla, Herceptin, Perjeta, Ontruzant, Herzuma

Top reporter: Genentech, Inc.

HER2/neu Receptor Antagonist [EPC]Microtubule Inhibitor [EPC]Nucleoside Metabolic Inhibitor [EPC]Aromatase Inhibitor [EPC]Corticosteroid [EPC]
8,277
Total Reports
4,446
Serious Reports
1,136
Death Reports
30
Reported Reactions
Death Report Ratio: High (13.72%)

Patient Demographics

Male
179
Female
6,834

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ado-Trastuzumab Emtansine.

# Reaction Reports % of Total
1 DISEASE PROGRESSION 781
6.9%
2 FATIGUE 751
6.6%
3 NAUSEA 732
6.4%
4 OFF LABEL USE 637
5.6%
5 DIARRHOEA 594
5.2%
6 DEATH 541
4.8%
7 THROMBOCYTOPENIA 468
4.1%
8 NEUROPATHY PERIPHERAL 453
4.0%
9 PLATELET COUNT DECREASED 433
3.8%
10 HEADACHE 431
3.8%
11 DRUG INEFFECTIVE 406
3.6%
12 METASTASES TO CENTRAL NERVOUS SYSTEM 404
3.6%
13 VOMITING 345
3.0%
14 PYREXIA 328
2.9%
15 EPISTAXIS 317
2.8%
16 WEIGHT DECREASED 316
2.8%
17 ASTHENIA 298
2.6%
18 DYSPNOEA 297
2.6%
19 PAIN 287
2.5%
20 PNEUMONIA 282
2.5%
21 CONSTIPATION 268
2.4%
22 MALIGNANT NEOPLASM PROGRESSION 255
2.2%
23 COUGH 243
2.1%
24 ANAEMIA 230
2.0%
25 RASH 230
2.0%
26 NO ADVERSE EVENT 224
2.0%
27 DECREASED APPETITE 208
1.8%
28 NASOPHARYNGITIS 208
1.8%
29 EJECTION FRACTION DECREASED 205
1.8%
30 NEUTROPENIA 196
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.